Differential MicroRNA Expression between EGFR T790M and L858R Mutated Lung Cancer

키워드

참고문헌 (44)

1. Miller KD, "Cancer treatment and survivorship statistics, 2016", CA Cancer J Clin, 66, pp.271~289 (2016)[DOI]
2. Mok TS, "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma", N Engl J Med, 361, pp.947~957 (2009)[DOI]
3. Denis MG, "EGFR T790M resistance mutation in non small-cell lung carcinoma", Clin Chim Acta, 444, pp.81~85 (2015)[DOI]
4. Engelman JA, "Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall cell lung cancer", Clin Cancer Res, 14, pp.2895~2899 (2008)[DOI]
5. Remon J, "Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins", Cancer Treat Rev, 40, pp.93~101 (2014)[DOI]
6. Garzon R, "MicroRNA expression and function in cancer", Trends Mol Med, 12, pp.580~587 (2006)[DOI]
7. Bloomston M, "MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis", JAMA, 297, pp.1901~1908 (2007)[DOI]
8. Kanaan Z, "Plasma miR-21: a potential diagnostic marker of colorectal cancer", Ann Surg, 256, pp.544~551 (2012)[DOI]
9. Hu Z, "Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer", J Clin Oncol, 28, pp.1721~1726 (2010)[DOI]
10. Pignot G, "microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer", Int J Cancer, 132, pp.2479~2491 (2013)[DOI]
11. Xu F, "Up-regulation of microRNA-183-3p is a potent prognostic marker for lung adenocarcinoma of female non-smokers", Clin Transl Oncol, 16, pp.980~985 (2014)[DOI]
12. Cho WC, "Restoration of tumour suppressor hsamiR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation", Eur J Cancer, 45, pp.2197~2206 (2009)[DOI]
13. Gao Y, "miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124", Biochem Biophys Res Commun, 446, pp.179~186 (2014)[DOI]
14. Wiggins JF, "Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34", Cancer Res, 70, pp.5923~5930 (2010)[DOI]
15. Betel D, "The microRNA. org resource: targets and expression", Nucleic Acids Res, 36, pp.D149~D153 (2008)
16. Subramanian A, "Gene set enrichment analysis: a knowledge-based approach for interpreting genomewide expression profiles", Proc Natl Acad Sci U S A, 102, pp.15545~15550 (2005)[DOI]
17. Sequist LV, "First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations", J Clin Oncol, 26, pp.2442~2449 (2008)[DOI]
18. Lynch TJ, "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib", N Engl J Med, 350, pp.2129~2139 (2004)[DOI]
19. Sos ML, "Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation", Cancer Res, 70, pp.868~874 (2010)[DOI]
20. Yun CH, "The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP", Proc Natl Acad Sci U S A, 105, pp.2070~2075 (2008)[DOI]
21. Chong CR, "The quest to overcome resistance to EGFRtargeted therapies in cancer", Nat Med, 19, pp.1389~1400 (2013)[DOI]
22. Camidge DR, "Acquired resistance to TKIs in solid tumours: learning from lung cancer", Nat Rev Clin Oncol, 11, pp.473~481 (2014)[DOI]
23. Yang JC, "Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component", J Clin Oncol, 35, pp.1288~1296 (2017)[DOI]
24. Sin TK, "Implications of microRNAs in the treatment of gefitinib-resistant non-small cell lung cancer", Int J Mol Sci, 17, pp.237~ (2016)[DOI]
25. Nohata N, "microRNA-1", 133a and microRNA-206, Oncotarget, pp.2012, 3[DOI]
26. Xiao H, "MiR-1 downregulation correlates with poor survival in clear cell renal cell carcinoma where it interferes with cell cycle regulation and metastasis", Oncotarget, 6, pp.13201~13215 (2015)
27. Han C, "Role of microRNA-1 in human cancer and its therapeutic potentials", Biomed Res Int, 2014, pp.428371~ (2014)
28. Chen Z, "miR-124 and miR-506 inhibit colorectal cancer progression by targeting DNMT3B and DNMT1", Oncotarget, 6, pp.38139~38150 (2015)
29. Furuta M, "miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma", Carcinogenesis, 31, pp.766~776 (2010)[DOI]
30. Dong LL, "Decreased expression of microRNA-124 is an independent unfavorable prognostic factor for patients with breast cancer", Diagn Pathol, 10, pp.45~ (2015)[DOI]
31. Lee Y, "Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung cancer", Clin Lung Cancer, 16, pp.46~50 (2015)[DOI]
32. Oxnard GR, "Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation", Clin Cancer Res, 17, pp.1616~1622 (2011)[DOI]
33. Hata A, "Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations", Cancer, 119, pp.4325~4332 (2013)[DOI]
34. Rosell R, "EGFR compound mutants and survival on erlotinib in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study", J Clin Oncol, 30(15 Suppl), pp.7522~ (2012)
35. Fujita Y, "Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation", J Thorac Oncol, 7, pp.1640~1644 (2012)[DOI]
36. Panarelli NC, "MicroRNA expression aids the preoperative diagnosis of pancreatic ductal adenocarcinoma", Pancreas, 41, pp.685~690 (2012)
37. Steele CW, "Clinical potential of microRNAs in pancreatic ductal adenocarcinoma", Pancreas, 40, pp.1165~1171 (2011)[DOI]
38. Chen C, "MicroRNA-196:critical roles and clinical applications in development and cancer", J Cell Mol Med, 15, pp.14~23 (2011)[DOI]
39. Kim SM, "Activation of IL-6R", JAK1, Mol Cancer Ther, pp.2012, 11[DOI]
40. Cheung HW, "Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers", Cancer Discov, 1, pp.608~625 (2011)[DOI]
41. Wu Z, "Up-regulation of miR-124 inhibits invasion and proliferation of prostate cancer cells through mediating JAK-STAT3 signaling pathway", Eur Rev Med Pharmacol Sci, 21, pp.2338~2345 (2017)
42. Lv Z, "MiR-124 inhibits the growth of glioblastoma through the downregulation of SOS1", Mol Med Rep, 8, pp.345~349 (2013)[DOI]
43. Chen LY, "Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: a systematic review and metaanalysis", Lung Cancer, 94, pp.46~53 (2016)[DOI]
44. Inukai M, "Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer", Cancer Res, 66, pp.7854~7858 (2006)[DOI]

관련 논문AI추천